One-year outcomes of the multi-center study to transplant hepatitis C-infected kidneys (MYTHIC) Trial | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

One-year outcomes of the multi-center study to transplant hepatitis C-infected kidneys (MYTHIC) Trial

Sise ME, Goldberg DS, Schaubel DE, et al. One-year outcomes of the multi-center study to transplant hepatitis C-infected kidneys (MYTHIC) Trial. Kidney Int Rep [Internet]. 2021;7(2):241-250. https://doi.org/10.1016/j.ekir.2021.11.022

Publication Type:

Journal Article

Authors:

Sise, ME; Goldberg, DS; Schaubel, DE; et, al

Source:

Kidney Int Rep, Volume 7, Issue 2, p.241-250 (2021)

URL:

https://doi.org/10.1016/j.ekir.2021.11.022

Keywords:

cytomegalovirus infection, Direct-acting antivirals, Glecaprevir/pibrentasvir, hepatitis C virus, Kidney Transplantation, organ allocation

Cited On:

Treatment of HCV-Uninfected Transplant Recipients Receiving Organs From HCV-Viremic Donors

External Third-party Web Link:

https://pubmed.ncbi.nlm.nih.gov/35155863/

Export Citation:

RIS Format

Top